Largest Real-World Evidence Study in Early-Stage Breast Cancer; FLEX Surpasses 25,000 Patients

IRVINE, Calif. & AMSTERDAM–(BUSINESS WIRE)–Agendia’s landmark FLEX Study reaches a major enrollment milestone, accelerating real-world insights to advance more personalized breast cancer care
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks